Back to top

Image: Bigstock

Johnson and Johnson, Inc.

Read MoreHide Full Article

Sales in J&J’s domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition.  However, J&J is optimistic that sales growth will accelerate in 2H17. We believe that new drugs like Xarelto, Stelara, Darzalex, and Imbruvica remain the key to growth. Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. The Actelion buy adds an attractive new therapeutic area – PAH – which should contribute to sales growth. J&J’s shares have outperformed the industry this year so far. However, headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern. Meanwhile, HCV sales continue to decline in the face of intense competition.
 


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Johnson & Johnson (JNJ) - free report >>

Published in